Recursion Pharmaceuticals, Inc. (RXRX)

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing....

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript...

Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive data from an ongoing trial....

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare gen...

SALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from ...

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?...

Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already ...

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

Handelsbanken Fonder AB boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) by 20.5% in the undefined quarter, according to the company in its most recent disclosure with ...

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) has received an average recommendation of "Hold" from the six ratings firms that are covering the company, Marketbeat Ratings reports. ...